Infectious Diseases Self-Assessment Program (IDSAP) Book 2: Infections in Special Populations (Cert # L249251)

The target audience for Infectious Diseases Self-Assessment Program (IDSAP) Book 2: Infections in Special Populations and is board-certified and advanced level infectious diseases clinical pharmacists.

Board-certified pharmacists are eligible to receive up to 23.5 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.   

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.

ACCP and ASHP are approved by BPS as a provider for the recertification of BCIDP .

Infections in Special Populations I
ACPE: 0217-9999-24-230-H02-P
Chapter: Perinatal Infections

• Assess current screening and prevention strategies for perinatal infections, including prenatal testing, vaccination programs, and interventions during labor and delivery.
• Develop a plan for monitoring and criteria for initiating acyclovir in a neonate born to a mother with genital history of herpes simplex virus.
• Design a treatment plan for prevention of hepatitis B infection in a newborn based on maternal serology.
• Assess medication regimen for a newborn born to a mother with HIV based on maternal risk factors.
• Develop a plan for counseling pregnant women about perinatal infections, addressing concerns with safety of medication during pregnancy and breastfeeding. 

Chapter: Neonatal Sepsis

• Analyze differences between risk factors and common organisms in early- versus late-onset neonatal sepsis.
• Assess patients for neonatal sepsis on the basis of clinical and laboratory values.
• Design an approach for evaluation and management of early-onset neonatal sepsis.
• Develop recommendations for the management of late-onset neonatal sepsis.
• Evaluate current guidelines for the treatment and prevention of neonatal candidiasis. 

Infections in Special Populations II
ACPE: 0217-9999-24-231-H02-P
Chapter: Pediatric Viral Infections

• Distinguish the differences between risk stratification and drug therapy recommendations for treatment of COVID-19 in pediatrics from the leading guidelines.
• Assess the differences in the various nucleoside and nucleotide analogs.
• Delineate the role and place in therapy of remdesivir in pediatrics for the treatment of acute COVID-19.
• Assess the differences in palivizumab and nirsevimab-alip in their efficacy, safety, cost, and availability for prevention of respiratory syncytial virus (RSV).
• Evaluate the latest data and availability of nirsevimab-alip for prevention of RSV. 

Chapter: Catheter-Related Bloodstream Infections

• Analyze risk factors and preventive strategies for catheter-related bloodstream infections (CRBSIs) in patients with various types of intravascular catheters.
• Assess patients with CRBSIs for indications for catheter removal and antimicrobial lock therapy.
• Develop empiric antimicrobial regimens for patients with CRBSIs on the basis of patient-specific factors.
• Design antimicrobial treatment plans for patients with CRBSIs on the basis of causative organism, catheter type, and patient-specific factors.
• Distinguish therapy durations for various CRBSIs. 

Infections in Special Populations III
ACPE: 0217-9999-24-232-H02-P
Chapter: Outpatient Parenteral Antimicrobial Therapy

• Design a plan to ensure compliance with the CDC core elements of antimicrobial stewardship related to outpatient parenteral antimicrobial therapy (OPAT).
• Develop patient-specific intravenous versus oral antimicrobial therapy recommendations according to evidence for the diagnosed infection.
• Apply this knowledge to determine the optimal antimicrobial on the basis of evidence, narrowest spectrum of activity, and patient-specific factors to be used for OPAT.
• Distinguish between various intravenous catheter options to determine the optimal choice for a given patient according to antimicrobial and duration of therapy.
• Develop an individualized plan for managing OPAT after initiation. 

Chapter: Pediatric Musculoskeletal Infections

• Compare and contrast pediatric and adult musculoskeletal infections.
• Distinguish between the different classifications of osteomyelitis, septic arthritis, and pyomyositis based on pathophysiology and site of infection.
• Develop an empiric treatment regimen for a pediatric patient with a musculoskeletal infection, accounting for clinical presentation, diagnosis, risk factors, patient characteristics and the most likely causative pathogens.
• Design a pediatric patient–specific treatment plan for musculoskeletal infection using the narrowest spectrum agent possible while achieving appropriate antimicrobial concentrations.
• Evaluate the duration of treatment of a musculoskeletal infection based on patient and infection specific factors. 

Infections in Special Populations IV
ACPE: 0217-9999-24-233-H02-P
Chapter: Sexually Transmitted Infections

• Evaluate the clinical presentations of different sexually transmitted infections (STIs).
• Identify the preferred and alternative treatments for most patients with STIs according to clinical practice guidelines.
• Evaluate pharmacotherapy options for the treatment of STIs in special populations, including pregnancy, pediatrics, and those with HIV infection.
• Design a pharmacotherapy treatment plan for patients with STIs. 

Chapter: Urinary Tract Infections

• Analyze patient risk factors and laboratory data to determine proper UTI classification and treatment duration.
• Assess current best practices for preventing catheter-associated UTIs.
• Distinguish clinical presentation of asymptomatic bacteriuria from uncomplicated UTIs in special patient populations.
• Develop antimicrobial treatment plans for patients with individual factors related to UTIs.
• Evaluate the pharmacologic options for multidrug-resistant uropathogens. 

Infections in Special Populations V
ACPE: 0217-9999-24-234-H02-P
Case Series: Appendicitis

• Evaluate a patient’s presenting signs, symptoms, and laboratory values to appropriately assign a risk score for appendicitis.
• Distinguish between a nonoperative and operative approach for patients with appendicitis on the basis of presentation, appendicitis classification, and other risk factors.
• Design an appropriate antibiotic regimen for the management of appendicitis.
• Design a discharge plan for a patient requiring continued antibiotic therapy.
• Develop a plan to treat complications stemming from primary management of appendicitis. 

Case Series: Pediatric Pneumonia

• Distinguish the most common causative pathogens for pediatric community-acquired pneumonia (CAP) on the basis of patient age.
• Develop antibiotic treatment regimens for pediatric patients with uncomplicated pneumonia while considering local and patient-specific factors.
• Design a medication management plan for pediatric patients presenting with complicated pneumonia.
• Analyze pediatric vaccination recommendations to aid in the prevention of CAP.

Faculty Information

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ACCP and ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships: 

Consultancies: Jason Child (LexiComp); David Cluck (Astellas); Sarah Jones (Wolters Kluwer); Christine MacBrayne (NIH); Holly D. Maples (Wolters Kluwer); Jessica Sobnosky (Shionogi Inc.); Riley Williams II (VPR/Sanofi) Stock Ownership: Jason Child (Baxter); Michelle Rychalsky (CVS Health)

Grants: Kailynn DeRonde (The Batchelor Foundation); Spencer Durham (NIH, Alabama Department of Public Health [two grants]); Jessica Sobnosky (VenatoRx Pharmaceuticals, NIH/ARLG); Jeremy Stultz (Marck Sharp and Dohme, Patient Center Outcomes Research Institute, National Institutes of Health, BPS, Pediatric Pharmacy Association, ACCP Foundation); Ann Wirtz (APIC)

Honoraria: Jessica Sobnosky (Melinta Therapeutics, Shionogi Inc.); Riley Williams II (VPR/Sanofi); Ann Wirtz (KC APIC)

ACCP Staff/Series Leaders
Consultancies: Elizabeth Dodds-Ashley (HealthTrackRX)
Grants: Alan Gross (AHRQ), Elizabeth Dodds Ashley (CDC)
Royalties: Elizabeth Dodds-Ashley (UpToDate)
Honoraria: Alan Gross (APhA; PROCE)

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

• Complete the attestation statement
• Review all content
• Complete and pass the assessments
• Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

ACCP and ASHP collaborate on infectious diseases activities.